Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Talphera. The associated price target remains the same with $3.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors that highlight Talphera’s promising future. The recent $29 million financing deal, which includes an upfront payment of $17 million, is expected to support the company through the approval process of its anticoagulant, Niyad, by the second half of 2026. This influx of capital alleviates concerns about Talphera’s financial capacity to complete its Phase 3 trial, with results anticipated by the end of 2025.
Moreover, the strategic option for CorMedix Inc. to acquire Talphera following a successful Phase 3 outcome presents an attractive exit opportunity for shareholders. CorMedix’s established market presence and successful product launches in the hospital setting, particularly with its product DefenCath, align well with Niyad’s target market. This potential acquisition, coupled with the promising market opportunity for Niyad, reinforces the Buy rating as it suggests a favorable outcome for both Talphera’s growth prospects and shareholder value.